Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013, Article ID 390482, 8 pages
http://dx.doi.org/10.1155/2013/390482
Research Article

High Expression of H3K27me3 Is an Independent Predictor of Worse Outcome in Patients with Urothelial Carcinoma of Bladder Treated with Radical Cystectomy

1State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China
2Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China
3Department of Pathology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, China

Received 23 May 2013; Accepted 31 July 2013

Academic Editor: Xin-yuan Guan

Copyright © 2013 Jianye Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Pelucchi, C. Bosetti, E. Negri, M. Malvezzi, and C. La Vecchia, “Mechanisms of disease: the epidemiology of bladder cancer,” Nature Clinical Practice Urology, vol. 3, no. 6, pp. 327–340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. M. S. Cookson, “The surgical management of muscle invasive bladder cancer: a contemporary review,” Seminars in Radiation Oncology, vol. 15, no. 1, pp. 10–18, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. P. Stein, G. Lieskovsky, R. Cote et al., “Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients,” Journal of Clinical Oncology, vol. 19, no. 3, pp. 666–675, 2001. View at Google Scholar · View at Scopus
  4. M. Esteller, “Molecular origins of cancer: epigenetics in cancer,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1148–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. D. Strahl and C. D. Allis, “The language of covalent histone modifications,” Nature, vol. 403, no. 6765, pp. 41–45, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. A. H. Lund and M. Van Lohuizen, “Epigenetics and cancer,” Genes and Development, vol. 18, no. 19, pp. 2315–2335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Cao, L. Wang, H. Wang et al., “Role of histone H3 lysine 27 methylation in polycomb-group silencing,” Science, vol. 298, no. 5595, pp. 1039–1043, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Matsukawa, S. Semba, H. Kato, A. Ito, K. Yanagihara, and H. Yokozaki, “Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer,” Cancer Science, vol. 97, no. 6, pp. 484–491, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Mimori, K. Ogawa, M. Okamoto, T. Sudo, H. Inoue, and M. Mori, “Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases,” European Journal of Surgical Oncology, vol. 31, no. 4, pp. 376–380, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Sudo, T. Utsunomiya, K. Mimori et al., “Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma,” British Journal of Cancer, vol. 92, no. 9, pp. 1754–1758, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Collett, G. E. Eide, J. Arnes et al., “Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer,” Clinical Cancer Research, vol. 12, no. 4, pp. 1168–1174, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Kidani, M. Osaki, T. Tamura et al., “High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas,” Oral Oncology, vol. 45, no. 1, pp. 39–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. D. Raman, N. P. Mongan, S. K. Tickoo, S. A. Boorjian, D. S. Scherr, and L. J. Gudas, “Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder,” Clinical Cancer Research, vol. 11, no. 24, pp. 8570–8576, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Wang, R. Albadine, A. Magheli et al., “Increased EZH2 protein expression is associated with invasive urothelial carcinoma of the bladder,” Urologic Oncology, vol. 30, no. 4, pp. 428–433, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Southgate, K. A. R. Hutton, D. F. M. Thomas, and L. K. Trejdosiewicz, “Normal human urothelial cells in vitro: proliferation and induction of stratification,” Laboratory Investigation, vol. 71, no. 4, pp. 583–594, 1994. View at Google Scholar · View at Scopus
  16. D. Xie, J. S. T. Sham, W.-F. Zeng et al., “Heterogeneous expression and association of β-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray,” International Journal of Cancer, vol. 107, no. 6, pp. 896–902, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Wei, W. Xia, Z. Zhang et al., “Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers,” Molecular Carcinogenesis, vol. 47, no. 9, pp. 701–706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Tzao, H.-J. Tung, J.-S. Jin et al., “Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus,” Modern Pathology, vol. 22, no. 2, pp. 252–260, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. K. Gospodarowicz, “Staging of bladder cancer,” Seminars in Surgical Oncology, vol. 10, no. 1, pp. 51–59, 1994. View at Google Scholar · View at Scopus
  20. B. P. Schrier, M. P. Hollander, B. W. G. Van Rhijn, L. A. L. M. Kiemeney, and J. A. Witjes, “Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy,” European Urology, vol. 45, no. 3, pp. 292–296, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. S. A. Hussain and N. D. James, “Molecular markers in bladder cancer,” Seminars in Radiation Oncology, vol. 15, no. 1, pp. 3–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. E. B. Lewis, “A gene complex controlling segmentation in Drosophila,” Nature, vol. 276, no. 5688, pp. 565–570, 1978. View at Google Scholar · View at Scopus
  23. K. H. Hansen, A. P. Bracken, D. Pasini et al., “A model for transmission of the H3K27me3 epigenetic mark,” Nature Cell Biology, vol. 10, no. 11, pp. 1291–1300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. Tonini, G. D'Andrilli, A. Fucito, L. Gaspa, and L. Bagella, “Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements,” Journal of Cellular Physiology, vol. 214, no. 2, pp. 295–300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Schlesinger, R. Straussman, I. Keshet et al., “Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer,” Nature Genetics, vol. 39, no. 2, pp. 232–236, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Widschwendter, H. Fiegl, D. Egle et al., “Epigenetic stem cell signature in cancer,” Nature Genetics, vol. 39, no. 2, pp. 157–158, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. V. Brock, J. G. Herman, and S. B. Baylin, “Cancer as a manifestation of aberrant chromatin structure,” Cancer Journal, vol. 13, no. 1, pp. 3–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Yu, J. Yu, D. R. Rhodes et al., “A polycomb repression signature in metastatic prostate cancer predicts cancer outcome,” Cancer Research, vol. 67, no. 22, pp. 10657–10663, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. T.-Y. Lu, C.-F. Kao, C.-T. Lin et al., “DNA methylation and histone modification regulate silencing of OPG during tumor progression,” Journal of Cellular Biochemistry, vol. 108, no. 1, pp. 315–325, 2009. View at Publisher · View at Google Scholar · View at Scopus